• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群、菌群失调与心房颤动。致心律失常机制及潜在临床意义。

Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications.

机构信息

1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Institute of Pharmacology, West German Heart and Vascular Centre, University Duisburg-Essen, Duisburg, Germany.

出版信息

Cardiovasc Res. 2022 Aug 24;118(11):2415-2427. doi: 10.1093/cvr/cvab292.

DOI:
10.1093/cvr/cvab292
PMID:34550344
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9400433/
Abstract

Recent preclinical and observational cohort studies have implicated imbalances in gut microbiota composition as a contributor to atrial fibrillation (AF). The gut microbiota is a complex and dynamic ecosystem containing trillions of microorganisms, which produces bioactive metabolites influencing host health and disease development. In addition to host-specific determinants, lifestyle-related factors such as diet and drugs are important determinants of the gut microbiota composition. In this review, we discuss the evidence suggesting a potential bidirectional association between AF and gut microbiota, identifying gut microbiota-derived metabolites as possible regulators of the AF substrate. We summarize the effect of gut microbiota on the development and progression of AF risk factors, including heart failure, hypertension, obesity, and coronary artery disease. We also discuss the potential anti-arrhythmic effects of pharmacological and diet-induced modifications of gut microbiota composition, which may modulate and prevent the progression to AF. Finally, we highlight important gaps in knowledge and areas requiring future investigation. Although data supporting a direct relationship between gut microbiota and AF are very limited at the present time, emerging preclinical and clinical research dealing with mechanistic interactions between gut microbiota and AF is important as it may lead to new insights into AF pathophysiology and the discovery of novel therapeutic targets for AF.

摘要

最近的临床前和观察性队列研究表明,肠道微生物群落组成的失衡可能是导致心房颤动(AF)的一个因素。肠道微生物群落是一个复杂而动态的生态系统,其中包含数以万亿计的微生物,这些微生物产生生物活性代谢物,影响宿主的健康和疾病发展。除了宿主特异性决定因素外,生活方式相关因素,如饮食和药物,也是肠道微生物群落组成的重要决定因素。在这篇综述中,我们讨论了肠道微生物群落与 AF 之间存在潜在双向关联的证据,确定了肠道微生物群落衍生的代谢物可能是 AF 底物的调节因子。我们总结了肠道微生物群对 AF 危险因素(包括心力衰竭、高血压、肥胖和冠心病)的发展和进展的影响。我们还讨论了通过药物和饮食改变肠道微生物群落组成的潜在抗心律失常作用,这些作用可能调节并预防向 AF 的进展。最后,我们强调了知识空白和需要未来研究的领域。尽管目前支持肠道微生物群与 AF 之间直接关系的数据非常有限,但新兴的临床前和临床研究处理肠道微生物群与 AF 之间的机制相互作用非常重要,因为它可能为 AF 病理生理学提供新的见解,并发现 AF 的新治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e76/9400433/cc71f55a0e96/cvab292ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e76/9400433/cc71f55a0e96/cvab292ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e76/9400433/cc71f55a0e96/cvab292ga1.jpg

相似文献

1
Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications.肠道微生物群、菌群失调与心房颤动。致心律失常机制及潜在临床意义。
Cardiovasc Res. 2022 Aug 24;118(11):2415-2427. doi: 10.1093/cvr/cvab292.
2
Association of gut microbiome dysbiosis with the progression of atrial fibrillation: A systematic review.肠道微生物群落失调与心房颤动进展的关联:系统评价。
Ann Noninvasive Electrocardiol. 2023 Jul;28(4):e13059. doi: 10.1111/anec.13059. Epub 2023 Mar 20.
3
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.固体器官移植受者的共生元、益生元和益生菌。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
4
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
5
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
6
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.慢性肾脏病患者的合生菌、益生元和益生菌。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013631. doi: 10.1002/14651858.CD013631.pub2.
7
Gut microbiome-based interventions for the management of obesity in children and adolescents aged up to 19 years.基于肠道微生物群的干预措施用于管理19岁及以下儿童和青少年的肥胖问题。
Cochrane Database Syst Rev. 2025 Jul 10;7(7):CD015875. doi: 10.1002/14651858.CD015875.
8
Dysbiosis and Neurodegeneration in ALS: Unraveling the Gut-Brain Axis.肌萎缩侧索硬化症中的微生物群失调与神经退行性变:揭示肠-脑轴
Neuromolecular Med. 2025 Jul 3;27(1):50. doi: 10.1007/s12017-025-08870-0.
9
Intestinal inflammation and microbiota modulation impact cochlear function: emerging insights in gut-ear axis.肠道炎症与微生物群调节影响耳蜗功能:肠道-耳轴的新见解
Cell Commun Signal. 2025 Jul 26;23(1):357. doi: 10.1186/s12964-025-02338-1.
10
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.体外电复律和药物复律治疗心房颤动、心房扑动或房性心动过速的网状 Meta 分析。
Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD013255. doi: 10.1002/14651858.CD013255.pub2.

引用本文的文献

1
Causal association between gut microbiota composition and the risk of atrial fibrillation.肠道微生物群组成与心房颤动风险之间的因果关联。
J Transl Int Med. 2025 Jun 20;13(3):241-252. doi: 10.1515/jtim-2025-0031. eCollection 2025 Jun.
2
Microbial Metabolites and Cardiovascular Dysfunction: A New Era of Diagnostics and Therapy.微生物代谢产物与心血管功能障碍:诊断与治疗的新时代。
Cells. 2025 Aug 11;14(16):1237. doi: 10.3390/cells14161237.
3
Aging-associated mechanisms of atrial fibrillation progression and their therapeutic potential.

本文引用的文献

1
Gut Microbiome-Derived Metabolite Trimethylamine N-Oxide Induces Aortic Stiffening and Increases Systolic Blood Pressure With Aging in Mice and Humans.肠道微生物组衍生代谢物三甲胺 N-氧化物可诱导小鼠和人类的主动脉僵硬,并随着年龄的增长而增加收缩压。
Hypertension. 2021 Aug;78(2):499-511. doi: 10.1161/HYPERTENSIONAHA.120.16895. Epub 2021 May 10.
2
Oxidative stress: a bystander or a causal contributor to atrial remodelling and fibrillation?氧化应激:是旁观者还是心房重构及颤动的因果促成因素?
Cardiovasc Res. 2021 Sep 28;117(11):2291-2293. doi: 10.1093/cvr/cvab124.
3
Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases.
心房颤动进展的衰老相关机制及其治疗潜力。
J Cardiovasc Aging. 2024 Dec;4(4). doi: 10.20517/jca.2024.12. Epub 2024 Nov 7.
4
Active Colitis-Induced Atrial Electrophysiological Remodeling.活动性结肠炎诱导的心房电生理重塑
Biomolecules. 2025 Jul 10;15(7):982. doi: 10.3390/biom15070982.
5
Inflammasome Signaling in Cardiac Arrhythmias: Linking Inflammation, Fibrosis, and Electrical Remodeling.心律失常中的炎性小体信号传导:连接炎症、纤维化和电重构
Int J Mol Sci. 2025 Jun 20;26(13):5954. doi: 10.3390/ijms26135954.
6
An Exploration of the Relationship Between Gut Virome and Cardiovascular Disease: A Comprehensive Review.肠道病毒组与心血管疾病关系的探索:一项综述
Rev Cardiovasc Med. 2025 Jun 24;26(6):36386. doi: 10.31083/RCM36386. eCollection 2025 Jun.
7
Impact of gut microbiome on atrial fibrillation: Mechanistic insights and future directions in individualized medicine.肠道微生物群对心房颤动的影响:个性化医学的机制见解与未来方向
World J Cardiol. 2025 Jun 26;17(6):107386. doi: 10.4330/wjc.v17.i6.107386.
8
Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.代谢功能障碍相关脂肪性肝病与心房颤动:发病机制综述
World J Cardiol. 2025 Jun 26;17(6):106147. doi: 10.4330/wjc.v17.i6.106147.
9
Detection of the genetic association of circulating Helicobacter pylori antibodies with atrial fibrillation.循环幽门螺杆菌抗体与心房颤动的遗传关联检测
Medicine (Baltimore). 2025 May 16;104(20):e42506. doi: 10.1097/MD.0000000000042506.
10
Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts.心房颤动中的心房心肌病:机制途径与新兴治疗理念
J Clin Med. 2025 May 7;14(9):3250. doi: 10.3390/jcm14093250.
肠道微生物群、益生菌和益生元在心血管疾病中的作用。
Molecules. 2021 Feb 22;26(4):1172. doi: 10.3390/molecules26041172.
4
Interleukin-1β, Oxidative Stress, and Abnormal Calcium Handling Mediate Diabetic Arrhythmic Risk.白细胞介素-1β、氧化应激与钙处理异常介导糖尿病性心律失常风险。
JACC Basic Transl Sci. 2021 Jan 20;6(1):42-52. doi: 10.1016/j.jacbts.2020.11.002. eCollection 2021 Jan.
5
NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias.NLRP3 炎性小体是肥胖诱导的心房心律失常的关键驱动因素。
Cardiovasc Res. 2021 Jun 16;117(7):1746-1759. doi: 10.1093/cvr/cvab024.
6
Role of the gut microbiota in type 2 diabetes and related diseases.肠道微生物群在 2 型糖尿病及相关疾病中的作用。
Metabolism. 2021 Apr;117:154712. doi: 10.1016/j.metabol.2021.154712. Epub 2021 Jan 23.
7
Effect of an Enriched Protein Drink on Muscle Mass and Glycemic Control during Combined Lifestyle Intervention in Older Adults with Obesity and Type 2 Diabetes: A Double-Blind RCT.富含蛋白质饮料对肥胖 2 型糖尿病老年患者联合生活方式干预期间肌肉质量和血糖控制的影响:一项双盲 RCT 研究。
Nutrients. 2020 Dec 28;13(1):64. doi: 10.3390/nu13010064.
8
Choline Metabolism and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Study.胆碱代谢与 PREDIMED 研究中心律失常和心力衰竭的风险。
Clin Chem. 2021 Jan 8;67(1):288-297. doi: 10.1093/clinchem/hvaa224.
9
Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者的疾病相关肠道微生物组和代谢组变化。
Nat Commun. 2020 Nov 18;11(1):5886. doi: 10.1038/s41467-020-19701-0.
10
The gut microbiome as a target for adjuvant therapy in obstructive sleep apnea.肠道微生物组作为阻塞性睡眠呼吸暂停辅助治疗的靶点。
Expert Opin Ther Targets. 2020 Dec;24(12):1263-1282. doi: 10.1080/14728222.2020.1841749. Epub 2020 Dec 4.